Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy

José L. Blanco, Julio S.G. Montaner, Vincent C. Marconi, Maria M. Santoro, Ariel E. Campos-Loza, Robert W. Shafer, Michael D. Miller, Roger Paredes, Richard Harrigan, Mihn L. Nguyen, Carlo F. Perno, Lucero A. Gonzalez-Hernandez, José M. Gatell

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)

Abstract

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. Background: Fixed-dose combination antiretroviral therapy administered as a singletablet regimen (STR) may improve virologic suppression rates. The effect of STRs on development of resistance when virologic failure occurs on STRs is not known.
Original languageEnglish
Pages (from-to)2531-2539
JournalAIDS
Volume28
Issue number17
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Antiretroviral treatment
  • Atripla
  • HIV-1 resistance
  • Single-tablet regimen

Fingerprint Dive into the research topics of 'Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy'. Together they form a unique fingerprint.

Cite this